MOR News and Press, MorphoSys AG From 11/20/23

2023-11-20 13:26:45 ET Summary MorphoSys AG has faced disappointments with some of its programs not performing well in trials and in the market. The company's recent acquisition of Constellation Pharma is seen as a desperate measure by analysts. The upcoming release of topline...

2023-11-19 18:59:11 ET Summary MorphoSys reported Q3 2023 earnings with underperformance in Monjuvi sales due to competition and market saturation. There is optimism surrounding the upcoming data readout for Pelabresib, a promising myelofibrosis treatment. The company has a he...

2023-11-17 15:00:53 ET More on the markets SPY: Sell The Rally - Historical Patterns Show Misplaced Optimism S&P 500: Forget The Year-End Rally The Message From 12 Post-CPI Charts The 12 least expected market outcomes of '24 - and how to trade them ...

2023-11-16 17:45:02 ET MorphoSys AG (MOR) Q3 2023 Earnings Conference Call November 16, 2023 08:00 AM ET Company Participants Julia Neugebauer - Head of IR Jean-Paul Kress - CEO Tim Demuth - Chief Research and Development Officer Lucinda Crabtree - CFO ...

2023-11-15 16:03:12 ET More on MorphoSys MorphoSys: Pelabresib Data Coming Out Soon, More Room To Run MorphoSys: Stable Liquidity Amid Challenging Markets I-Mab gains FDA breakthrough tag for kidney disease therapy MorphoSys expects a 5% surge in Monjuvi sale...

– Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 – Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third quarter of 2023 – U.S. FDA granted ...

The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...

MorphoSys AG (MOR) is expected to report $-0.49 for Q3 2023

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST). MorphoSys' Management team wil...

2023-11-08 15:07:59 ET More on Xencor Xencor, Inc. (XNCR) Q3 2023 Earnings Call Transcript Xencor: Data In Early 2024 Could Bring Shareholder Value Xencor: A Mid-Stage Clinical Company With Falling Losses Xencor GAAP EPS of -$0.40 beats by $0.31, revenue of $...